SCHEMBL7950201

SCHEMBL7950201

Nc1c(F)cc(Cl)cc1-c1cccnc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.47
CYP2A6 P11509 3/20 0.46
EPHB4 P54760 1/20 0.46
NQO2 P16083 2/20 0.46
ADORA2A P29274 2/20 0.46
ADORA2B P29275 2/20 0.46
TDO2 P48775 2/20 0.44
MEN1 O00255 3/20 0.44
MKNK1 Q9BUB5 2/20 0.44
MKNK2 Q9HBH9 2/20 0.44
PSIP1 O75475 1/20 0.44
AXL P30530 1/20 0.44
ERN1 O75460 1/20 0.43
CYP17A1 P05093 3/20 0.43
CYP11B1 P15538 3/20 0.43
CYP11B2 P19099 3/20 0.43
CYP3A4 P08684 3/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 1/20 0.42
BCHE P06276 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28115752 0.80 CYP2A6 (0.51) PDK2CYP2A6TDO2MEN1ERN1
SCHEMBL2649494 0.76 AXL (0.56) CYP2A6EPHB4TDO2MEN1MKNK1
SCHEMBL3946385 0.76 IDO1 (0.53) PDK2CYP2A6TDO2MEN1MKNK1
SCHEMBL27810036 0.75 CYP11B2 (0.42) PDK2CYP2A6EPHB4TDO2MEN1
SCHEMBL2408057 0.74 PTGS1 (0.49) PDK2CYP2A6EPHB4TDO2ERN1
SCHEMBL24568403 0.73 KDM4E (0.47) EPHB4ADORA2AERN1CYP17A1CYP11B1
SCHEMBL3094447 0.72 AXL (0.56) CYP2A6TDO2MEN1MKNK1MKNK2
SCHEMBL21999637 0.72 TDO2 (0.48) CYP2A6TDO2MEN1MKNK1MKNK2
SCHEMBL20757515 0.72 PARP1 (0.46) CYP2A6TDO2MEN1MKNK1MKNK2
SCHEMBL15624620 0.71 TDO2 (0.56) CYP2A6TDO2ERN1CYP17A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082129-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-04-07 US disclosed
WO-2009156462-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082129-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 PDK2 1126/4885CYP2A6 56/4885EPHB4 3149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.